NCT06592482View on ClinicalTrials.gov

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Renal Impairment
Interventions
DRUG

AZD0780

"A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water."

Trial Locations (5)

32808

Research Site, Orlando

32809

Research Site, Orlando

33014

Research Site, Hialeah

55114

Research Site, Saint Paul

92630

Research Site, Lake Forest

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06592482 - A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 | Biotech Hunter | Biotech Hunter